- tossa Therapeutics (ATOS +3.1%) has announced blinded preliminary results from Phase 1 study evaluating AT-301 administered by nasal spray, for the treatment of COVID-19.
- AT-301 under development for at home use, was found to be safe and well tolerated at two different dose levels in both single and multiple dose forms over 14 days.
- There we no serious adverse events, no discontinuations, and only one subject of the 32 subjects experienced moderate adverse events and all other adverse events were mild in intensity.
- The company is preparing for a pre-IND meeting request with the FDA, planned to be submitted in the next 30 days.
- Atossa also plans to develop its nasal spray to potentially help prevent COVID-19 infection.
- In September, the investigational med received second positive safety review.
- https://seekingalpha.com/news/3634385-atossas-covidminus-19-nasal-spray-safe-in-early-stage-study
Tuesday, November 10, 2020
Atossa's COVID-19 nasal spray 'safe' in early-stage study
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.